Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of HRS-9813 in Healthy Subjects
NCT06939504Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- May 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HRS-9813 in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Hengrui Therapeutics. Primary endpoints: Maximum observed concentration of HRS-9813 capsule, Maximum observed concentration of HRS-9813 tablet and 2 more. Started May 2025; status: completed.
02
Drugs
HRS-9813
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06939504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06939504.